About cytosorbents - CTSO
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
CTSO At a Glance
CytoSorbents Corp.
305 College Road East
Princeton, New Jersey 08540
| Phone | 1-732-329-8885 | Revenue | 37.06M | |
| Industry | Medical Specialties | Net Income | -8,198,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 4.126% | |
| Fiscal Year-end | 12 / 2026 | Employees | 129 | |
| View SEC Filings |
CTSO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.073 |
| Price to Book Ratio | 6.801 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.99 |
| Enterprise Value to Sales | 1.697 |
| Total Debt to Enterprise Value | 0.467 |
CTSO Efficiency
| Revenue/Employee | 287,310.078 |
| Income Per Employee | -63,550.388 |
| Receivables Turnover | 4.909 |
| Total Asset Turnover | 0.752 |
CTSO Liquidity
| Current Ratio | 2.125 |
| Quick Ratio | 1.581 |
| Cash Ratio | 0.644 |
CTSO Profitability
| Gross Margin | 71.476 |
| Operating Margin | -38.418 |
| Pretax Margin | -23.201 |
| Net Margin | -22.119 |
| Return on Assets | -16.629 |
| Return on Equity | -96.391 |
| Return on Total Capital | -23.234 |
| Return on Invested Capital | -22.766 |
CTSO Capital Structure
| Total Debt to Total Equity | 497.747 |
| Total Debt to Total Capital | 83.271 |
| Total Debt to Total Assets | 61.674 |
| Long-Term Debt to Equity | 483.991 |
| Long-Term Debt to Total Capital | 80.969 |